Locations
Watertown, MA, USA · Cambridge, MA, USA · Cambridge, MA, USA
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Other
founded in
2018
Acrivon Therapeutics is a clinical stage oncology company leveraging its proprietary AP3 precision medicine platform to develop targeted therapies aimed at improving patient outcomes in cancer treatment. The company focuses on matching drug mechanisms to the biological drivers of cancer, utilizing its Onco Signature companion diagnostics to identify patients who will benefit from its therapies. Acrivon's lead program, ACR-368, is a selective kinase inhibitor currently in phase 2 clinical development, demonstrating promising anti-tumor activity across various solid cancer types. With a commitment to addressing significant unmet needs in oncology, Acrivon is positioned to make a substantial impact in precision oncology through its innovative approach and advanced pipeline.
Something looks off?On-site & Remote